克罗恩病:超出了瘤亡因子的对手
Laurent Peyrin-Biroulet1, Pierre Desreumaux, William J Sandborn
1Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France.
由于对瘤坏死因子对抗剂的可变反应,需要用于克罗恩病的新疗法. 研究正在转向加强肠道屏障,并与获得的免疫系统一起准先天免疫力.
科学领域:
- 胃肠道学和免疫学
- 药物开发 药物开发
- 炎症性肠道疾病研究研究
背景情况:
- 瘤亡因子 (TNF) 抗剂在克罗恩病中已经显示出治疗效益,但响应变异性需要新的治疗策略.
- 了解克罗恩病的病理生理学已经进步,突出了获得免疫系统 (淋巴细胞,细胞因子,粘附分子) 的作用.
- 新出现的证据涉及天生的免疫系统和肠道上皮,促使人们转向加强屏障.
研究的目的:
- 审查克罗恩病新型治疗剂的作用机制.
- 根据临床试验数据评估新药的疗效和不良事件.
- 讨论未来的治疗方向和药物开发的最佳终点.
主要方法:
- 审查现有的文献和临床试验数据关于克罗恩病的新疗法.
- 对药物机制的分析,针对既获得的,又天生的免疫路径.
- 评估研究药物的疗效和安全性概况.
主要成果:
- 新的治疗药物正在开发中,具有不同的作用机制.
- 临床试验提供了这些新型药物的疗效和不良事件的数据.
- 治疗场景正在发展,超越免疫抑制,包括障碍增强.
结论:
- 克罗恩病的新型治疗策略正在出现,解决目前治疗方法的局限性.
- 强化肠道屏障和调节先天免疫力的模式转变是显而易见的.
- 未来的研究应该专注于开发新的药物,以优化终点来改善患者的治疗结果.
更多相关视频
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
08:37Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease III: Crohn's Disease
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease II: Ulcerative Colitis
